Home Other Building Blocks 875787-07-8
875787-07-8,MFCD16495812
Catalog No.:AA00GU1A

875787-07-8 | Lxr-623

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$34.00   $24.00
- +
5mg
98%
in stock  
$83.00   $58.00
- +
10mg
98%
in stock  
$124.00   $87.00
- +
25mg
98%
in stock  
$214.00   $150.00
- +
50mg
98%
in stock  
$368.00   $258.00
- +
1000mg
98% by HPLC
in stock  
$6,295.00   $4,407.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00GU1A
Chemical Name:
Lxr-623
CAS Number:
875787-07-8
Molecular Formula:
C21H12ClF5N2
Molecular Weight:
422.7784
MDL Number:
MFCD16495812
SMILES:
Fc1ccc(cc1)c1n(Cc2ccc(cc2Cl)F)nc2c1cccc2C(F)(F)F
Properties
Computed Properties
 
Complexity:
554  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
6  
Rotatable Bond Count:
3  
XLogP3:
6.5  

Literature

Title: Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.

Journal: European heart journal 20120101

Title: Recent progress in liver X receptor-selective modulators.

Journal: Current opinion in drug discovery & development 20100701

Title: Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.

Journal: Journal of medicinal chemistry 20100422

Title: Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.

Journal: Bioorganic & medicinal chemistry letters 20100115

Title: LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

Journal: Journal of lipid research 20091201

Title: Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants.

Journal: Journal of clinical pharmacology 20090601

Title: Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.

Journal: Journal of medicinal chemistry 20081127

Title: Villa GR, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14;30(5):683-693.

Title: Giannarelli C, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2012 Jan;33(2):264-73.

Title: Quinet EM, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009 Dec;50(12):2358-70.

Title: DiBlasio-Smith EA, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med. 2008 Oct 16;6:59.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 875787-07-8
Tags:875787-07-8 Molecular Formula|875787-07-8 MDL|875787-07-8 SMILES|875787-07-8 Lxr-623